Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.2K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.4K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

From fatal disease to functional cure: 25 years of tyrosine kinase inhibition in chronic myeloid leukemia.

Leukemia·2026
Same author

Development of mirror-image monobodies targeting the oncogenic BCR::ABL1 kinase.

Nature communications·2024
Same author

Cytosolic delivery of monobodies using the bacterial type III secretion system inhibits oncogenic BCR: ABL1 signaling.

Cell communication and signaling : CCS·2024
Same author

The e13a3 (b2a3) and e14a3 (b3a3) BCR::ABL1 isoforms are resistant to asciminib.

Leukemia·2024
Same author

BCR::ABL1 kinase N-lobe mutants confer moderate to high degrees of resistance to asciminib.

Blood·2024
Same author

Improving the pharmacokinetics, biodistribution and plasma stability of monobodies.

Frontiers in pharmacology·2024

Related Experiment Video

Updated: Apr 16, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

941

Targeting BCR-ABL and JAK2 in Ph+ ALL.

Oliver Hantschel1

  • 1SWISS INSTITUTE FOR EXPERIMENTAL CANCER RESEARCH (ISREC).

Blood
|February 28, 2015
PubMed
Summary

Combined targeting of BCR-ABL kinase and Janus kinase 2 (JAK2) with dasatinib and ruxolitinib significantly prolonged survival and prevented resistance in a mouse model of Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL).

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL) is an aggressive hematologic malignancy.
  • Targeting the BCR-ABL kinase is a standard treatment for Ph+ ALL.
  • Mechanisms of resistance can limit the efficacy of BCR-ABL inhibitors.

Purpose of the Study:

  • To investigate the efficacy of combined dasatinib and ruxolitinib therapy.
  • To evaluate the impact on survival and resistance in a Ph+ ALL mouse model.

Main Methods:

  • Utilized a mouse model of Philadelphia chromosome–positive acute lymphoblastic leukemia.
  • Administered dasatinib to target BCR-ABL kinase.
  • Administered ruxolitinib to target Janus kinase 2 (JAK2).

More Related Videos

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.8K
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.4K

Related Experiment Videos

Last Updated: Apr 16, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

941
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.8K
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.4K

Main Results:

  • Combined dasatinib and ruxolitinib treatment resulted in prolonged survival.
  • The combination therapy demonstrated prevention of resistance development.
  • Evidence suggests synergistic effects of targeting both BCR-ABL and JAK2 pathways.

Conclusions:

  • Combined targeting of BCR-ABL and JAK2 pathways offers a promising therapeutic strategy for Ph+ ALL.
  • This combination may overcome resistance mechanisms and improve patient outcomes.
  • Further clinical investigation is warranted to translate these findings.